HHS Terminates COVID-19 Emergency Declarations, Shifting Treatment Landscape

The COVID-19 public health emergency (PHE) declaration, initially enacted in January 2020, provided HHS with broad authority to waive or modify certain requirements under Medicare, Medicaid, and CHIP, and to issue emergency use authorizations for medical products. These provisions allowed for rapid development, deployment, and reimbursement of vaccines, diagnostic tests, and therapeutic agents. The termination of the PHE, alongside the national emergency declaration, signifies a formal end to this extraordinary period of federal intervention in healthcare delivery.

This change means that many of the flexibilities and funding streams established during the emergency will expire. For instance, the federal government's direct purchasing and distribution of COVID-19 vaccines and treatments, which ensured broad access regardless of insurance status, will largely cease. Instead, these products will transition to commercial markets, with pricing and coverage determined by manufacturers and private insurers or government programs like Medicare and Medicaid.

The Operational Shift

The immediate impact on clinical practice centers on access to diagnostics and therapeutics. During the PHE, COVID-19 tests, including PCR and rapid antigen tests, were often available at no out-of-pocket cost, supported by federal funding. That coverage has now largely ended. Patients will face co-pays or full costs for tests, depending on their insurance plans and the setting of care. This could reduce testing rates, potentially hindering early diagnosis and timely initiation of antiviral treatments.

Antiviral therapies like Paxlovid (nirmatrelvir/ritonavir) and remdesivir, which received EUAs and were procured and distributed by the federal government, are also transitioning. While existing federal stockpiles of these drugs will be depleted, future supplies will be purchased through commercial channels. This means that while the drugs remain available, their cost and accessibility will depend on individual insurance coverage and pharmacy benefit managers. The EUA status for these drugs will eventually be replaced by full FDA approval, but the immediate change is in the funding mechanism, not necessarily the regulatory status of the drugs themselves.

Vaccines, too, will see a significant shift. The federal government previously purchased and distributed COVID-19 vaccines free of charge to all individuals. With the end of the PHE, vaccine procurement will move to the commercial market. Private insurance, Medicare, and Medicaid will cover the cost of recommended COVID-19 vaccines, similar to how other routine immunizations are handled. Uninsured individuals may face challenges accessing vaccines without specific state or federal programs in place to cover costs, though the Vaccines for Children program will continue to cover COVID-19 vaccines for eligible children.

Telehealth flexibilities, which expanded access to virtual care during the pandemic, are also affected. Many of the waivers allowing for broader telehealth reimbursement and cross-state practice expired with the PHE. Some of these flexibilities were extended by Congress through December 31, 2024, but the long-term landscape for telehealth reimbursement and licensure remains in flux. Clinicians relying on these expanded telehealth services must now ensure compliance with state-specific regulations and insurer policies.

Data collection and reporting also change. During the emergency, hospitals and states were required to report specific COVID-19 data to federal agencies, including case numbers, hospitalizations, and deaths. These mandatory reporting requirements have largely ceased, transitioning to voluntary reporting or integration into existing public health surveillance systems. This could lead to less comprehensive, real-time data on disease prevalence and severity, making it harder for clinicians and public health officials to track outbreaks and allocate resources effectively.

The termination of the PHE does not mean COVID-19 has disappeared. It simply means the federal government's emergency response framework has been dismantled. The virus continues to circulate, and clinicians will continue to manage patients with acute infection and long COVID. The shift requires a re-evaluation of practice workflows, patient education regarding costs, and an understanding of evolving insurance coverage for what is now considered an endemic respiratory virus.